PMID- 33610676
OWN - NLM
STAT- MEDLINE
DCOM- 20211224
LR  - 20211224
IS  - 1878-5492 (Electronic)
IS  - 0966-3274 (Linking)
VI  - 66
DP  - 2021 Jun
TI  - Analysis of HLA haplotype and clinical factors during hematopoietic stem cell 
      transplantation.
PG  - 101376
LID - S0966-3274(21)00016-2 [pii]
LID - 10.1016/j.trim.2021.101376 [doi]
AB  - BACKGROUND: The human leukocyte antigen (HLA) haplotype of the recipient in 
      hematopoietic stem cell transplantation (HSCT) is a key factor in its success or 
      failure. We analyzed the relationship between HLA haplotype frequency and 
      associated clinical factors in HSCT patients. METHODS: Patients who underwent 
      allogeneic HSCT between 2000 and 2019 at our institution were enrolled in this 
      study. The HSCT composition was 77 bone marrow transplantations (BMT), 38 
      peripheral blood stem cell transplantations (PBSCT), and 36 cord blood 
      transplantations (CBT). Patients were classified into three groups according to 
      their donor HLA haplotype frequency in the Japan Population: group A, top 1-10 
      haplotypes; group B, top 11-100 haplotypes; and group C, haplotype 101-. We then 
      compared various items including clinical biomarkers with the HLA haplotype 
      frequency. RESULTS: A significant negative correlation was identified between 
      older persons and length of survival. There are also significant correlations 
      between survival and levels of immunoglobulin G, D-dimer, and C-reactive protein, 
      as well as the platelet-large cell ratio before transplantation. A total of 96, 
      30, and 25 patients were classified into groups A, B, and C, respectively. The 
      HSCT match rate was significantly higher in group A patients than in those of 
      groups B and C. In contrast, the death rate, D-dimer level, and length of time 
      for engraftment were significantly higher in group B and C patients than in those 
      of group A. CONCLUSION: An assessment of transplant-related complications is 
      important in improving the performance of HSCT. The present data suggest that a 
      special therapeutic strategy is necessary for HSCT using low-frequency HLA 
      haplotypes.
CI  - Copyright (c) 2021 Elsevier B.V. All rights reserved.
FAU - Konishi, Akiko
AU  - Konishi A
AD  - First Department of Internal Medicine, Kansai Medical University, Japan.
FAU - Abe, Misao
AU  - Abe M
AD  - Division of Blood Transfusion, Kansai Medical University, Japan.
FAU - Yamaoka, Manabu
AU  - Yamaoka M
AD  - Division of Blood Transfusion, Kansai Medical University, Japan.
FAU - Satake, Atsushi
AU  - Satake A
AD  - First Department of Internal Medicine, Kansai Medical University, Japan.
FAU - Ito, Tomoki
AU  - Ito T
AD  - First Department of Internal Medicine, Kansai Medical University, Japan.
FAU - Nomura, Shosaku
AU  - Nomura S
AD  - First Department of Internal Medicine, Kansai Medical University, Japan. 
      Electronic address: shosaku-n@mbp.ocn.ne.jp.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20210219
PL  - Netherlands
TA  - Transpl Immunol
JT  - Transplant immunology
JID - 9309923
RN  - 0 (HLA Antigens)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Female
MH  - HLA Antigens/*immunology
MH  - Haplotypes/*immunology
MH  - *Hematopoietic Stem Cell Transplantation
MH  - Humans
MH  - Japan
MH  - Male
MH  - Middle Aged
MH  - Retrospective Studies
MH  - Transplantation, Homologous
OTO - NOTNLM
OT  - Clinical biomarker
OT  - Death rate
OT  - HLA haplotype
OT  - HSCT
OT  - Survival rate
EDAT- 2021/02/22 06:00
MHDA- 2021/12/25 06:00
CRDT- 2021/02/21 20:29
PHST- 2021/01/15 00:00 [received]
PHST- 2021/02/03 00:00 [revised]
PHST- 2021/02/14 00:00 [accepted]
PHST- 2021/02/22 06:00 [pubmed]
PHST- 2021/12/25 06:00 [medline]
PHST- 2021/02/21 20:29 [entrez]
AID - S0966-3274(21)00016-2 [pii]
AID - 10.1016/j.trim.2021.101376 [doi]
PST - ppublish
SO  - Transpl Immunol. 2021 Jun;66:101376. doi: 10.1016/j.trim.2021.101376. Epub 2021 
      Feb 19.